The observation of curative effects on the treatment of advanced gastric cancer by CIK cells combined with Docetaxel, Oxaliplation and S-1

Chinese Journal of Cancer Biotherapy

Volumn 22, Issue 3, 2015, Pages 381-384

  Xu, Quanxiao ^a   Chang, Zhanguo ^a   Zhang, Xiaodong ^a   Ma, Lei ^a   He, Limin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84935115949     PISSN: 1007385X     EISSN: None     Source Type: Journal    
DOI: 10.3872/j.issn.1007-385X.2015.3.018     Document Type: Article

References (8)

1. Wang M, Wu M, Wang W,et al. Docetexal plus S-l versus oxali- platin plus S-l for first-line treatment of patients with advanced gastric cancer: A retrospective study [J]. Oncol Res Treat, 2014, 37(1/2): 24-28.
2. Park I,Ryu MH,Choi YH,et al. A phase ü study of neoadjuvant docetaxel, oxaliplatin, S-l (DOS) chemotherapy followed by surgery and adjuvant S-l chemotherapy in and potentially resectable gastric or gastroesophageal junction adenocarcinoma [J]. Cancer Chemother Pharmacol, 2013, 72(4): 815-823.
3. Wang D, Zhang B, Gao H, et al. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer [J]. BMC Cancer, 2014, 10(14): 251-252.
4. Zhao M, Li H, Li L, et al. Impact of cellular immune function on prognosis of lung cancer patients after cytokine-induced killer cell therapy [J]. Asian Pac J Cancer Prev, 2014, 15(15): 6009- 6014.
5. Li JJ, Gu MF, Pan K, et al. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma [J]. J Immunother, 2012, 35(2): 189-195.
6. Yu X, Zhao H, Liu L. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma [J]. J Clin Immunol, 2014, 34(2): 194-203.
7. Shurin MR. Dual role of immunomodulation by anticancer chemotherapy [J]. Nat Med,2013, 19(1): 20-22.
8. Champiat S, Ileana E, Giaccone G, et al. Incorporating immune- checkpiont inhibitoes into systemic therapy of NSCLC [J]. J Thorne Oncol, 2014, 9(2): 144-153.